0
Editorials |

Rebuttal From Dr Rivers et alRebuttal From Dr Rivers et al

Emanuel P. Rivers, MD, MPH, FCCP; Ronald Elkin, MD; Chad M. Cannon, MD
Author and Funding Information

From the Department of Emergency Medicine and Surgery (Dr Rivers), Henry Ford Hospital, Wayne State University; Department of Medicine (Dr Elkin), Pulmonary and Critical Care Medicine, California Pacific Medical Center; and Department of Emergency Medicine (Dr Cannon), University of Kansas Hospital.

Correspondence to: Emanuel P. Rivers, MD, MPH, FCCP, Department of Emergency Medicine, Wayne State University, 270 Clara Ford Pavilion, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202; e-mail: erivers1@hfhs.org

CONSORT = Consolidated Standards of Reporting Trials; CVP = central venous pressure; Do2 = systemic oxygen delivery; EGDT = early goal directed therapy; LC = lactate clearance; Scvo2 = central venous oxygen saturation; SSC = surviving sepsis campaign.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: In the past 3 years, Dr Rivers has received funding from the National Institutes of Health, Aggennix AG, and Alere Corporation. He has been a one-time consultant for Aggennix AG; Eisai Co, Ltd; Idaho Technologies Inc; AstraZeneca; Massimo; and Sangard. He is a consultant to the Institute of Medicine, National Academies. The Early Goal-Directed Therapy (EGDT) study was performed without external industry support or funding of any kind. Any intellectual properties associated with Dr Rivers’ research are exclusively owned by Henry Ford Hospital. Dr Rivers holds no past or present intellectual properties and has never received royalties or stock interest related to technologies in EGDT research and practice. Dr Elkin has received funding from the Gordon and Betty Moore Foundation, has been a one-time consultant for Eisai Co, Ltd, and participated on the speaker’s bureau for Edwards Lifesciences LLC on three occasions. Dr Cannon has been a one-time consultant for Aggennix AG and Eisai Co, Ltd.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: In the past 3 years, Dr Rivers has received funding from the National Institutes of Health, Aggennix AG, and Alere Corporation. He has been a one-time consultant for Aggennix AG; Eisai Co, Ltd; Idaho Technologies Inc; AstraZeneca; Massimo; and Sangard. He is a consultant to the Institute of Medicine, National Academies. The Early Goal-Directed Therapy (EGDT) study was performed without external industry support or funding of any kind. Any intellectual properties associated with Dr Rivers’ research are exclusively owned by Henry Ford Hospital. Dr Rivers holds no past or present intellectual properties and has never received royalties or stock interest related to technologies in EGDT research and practice. Dr Elkin has received funding from the Gordon and Betty Moore Foundation, has been a one-time consultant for Eisai Co, Ltd, and participated on the speaker’s bureau for Edwards Lifesciences LLC on three occasions. Dr Cannon has been a one-time consultant for Aggennix AG and Eisai Co, Ltd.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: In the past 3 years, Dr Rivers has received funding from the National Institutes of Health, Aggennix AG, and Alere Corporation. He has been a one-time consultant for Aggennix AG; Eisai Co, Ltd; Idaho Technologies Inc; AstraZeneca; Massimo; and Sangard. He is a consultant to the Institute of Medicine, National Academies. The Early Goal-Directed Therapy (EGDT) study was performed without external industry support or funding of any kind. Any intellectual properties associated with Dr Rivers’ research are exclusively owned by Henry Ford Hospital. Dr Rivers holds no past or present intellectual properties and has never received royalties or stock interest related to technologies in EGDT research and practice. Dr Elkin has received funding from the Gordon and Betty Moore Foundation, has been a one-time consultant for Eisai Co, Ltd, and participated on the speaker’s bureau for Edwards Lifesciences LLC on three occasions. Dr Cannon has been a one-time consultant for Aggennix AG and Eisai Co, Ltd.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


Chest. 2011;140(6):1415-1419. doi:10.1378/chest.11-2599
Text Size: A A A
Published online

Extract

1LevrautJIchaiCPetitICiebieraJPPerusOGrimaudDLow exogenous lactate clearance as an early predictor of mortality in normolactatemic critically ill septic patientsCrit Care Med20033137057102JonesAEPoint: should lactate clearance be substituted for central venous oxygen saturation as goals of early severe sepsis and septic shock therapy? YesChest20111406140614083GattinoniLBrazziLPelosiPA trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative GroupN Engl J Med199533316102510324ChamberlainDJWillisEMBerstenABThe severe sepsis bundles as processes of care: a meta-analysis [published online ahead of print February 14, 2011]Aust Crit Care5JansenTCvan BommelJSchoonderbeekFJLACTATE study groupEarly lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trialAm J Respir Crit Care Med201018267527616PiaggioGElbourneDRAltmanDGPocockSJEvansSJCONSORT GroupReporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statementJAMA200629510115211607JonesAEShapiroNITrzeciakSArnoldRCClaremontHAKlineJAEmergency Medicine Shock Research Network (EMShockNet) InvestigatorsLactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trialJAMA201030387397468RiversEPPoint: adherence to early goal-directed therapy: does it really matter? Yes. After a decade, the scientific proof speaks for itselfChest201013834764809DellingerRPLevyMMCarletJMInternational Surviving Sepsis Campaign Guidelines CommitteeAmerican Association of Critical-Care NursesAmerican College of Chest PhysiciansAmerican College of Emergency PhysiciansCanadian Critical Care SocietyEuropean Society of Clinical Microbiology and Infectious DiseasesEuropean Society of Intensive Care MedicineEuropean Respiratory SocietyInternational Sepsis ForumJapanese Association for Acute MedicineJapanese Society of Intensive Care MedicineSociety of Critical Care MedicineSociety of Hospital MedicineSurgical Infection SocietyWorld Federation of Societies of Intensive and Critical Care MedicineSurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008Crit Care Med200836129632710LewisRJDisassembling goal-directed therapy for sepsis: a first stepJAMA20103038777779

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543